Kliničke studije za Debljina u državi Arizona
40 studija za Debljina traži sudionike na lokacijama u državi Arizona.
Gradovi u državi Arizona
- Phoenix22 studija
- Tucson17 studija
- Scottsdale6 studija
- Chandler5 studija
- Peoria4 studija
- Gilbert4 studija
- Mesa3 studija
Službeni tekst studije (engleski)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Headlands Research - Scottsdale /ID# 282571, Scottsdale
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07752979A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Pima Heart, Tucson
- Eclipse Clinical Research, Tucson
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07783802Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Tempe
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07837973Early Tracking of Childhood Health Determinants (ETCHED) Study
- NIDDK, Phoenix, Phoenix
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
1 Day – 99 Years · Oba spola · Ažurirano 28. ruj 2026. · NCT03481829A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Arizona, Tucson
U tijeku regrutacijaFaza 3
Od 6 do 17 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Tucson Clinical Research Institute, Tucson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- RIO Clinical Trials - Phoenix, Phoenix
- Headlands Research - Scottsdale, Scottsdale
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Mesa
- Research Site, Phoenix
- Research Site, Tucson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Headlands Research - Scottsdale, Scottsdale
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07321886Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Care Access - 801 South Power Road, Mesa, Mesa
- Elite Pain and Spine Institute - South Crimson Road, Mesa
- Elite Clinical Studies, LLC, Phoenix
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
- Headlands Research - Scottsdale, Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07589608Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NIDDK, Phoenix, Phoenix
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 99 godina · Oba spola · Ažurirano 21. ruj 2026. · NCT06223555A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Phoenix
- AURORA-1 Clinical Site, Tucson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Peoria
- AURORA-2 Clinical Site, Phoenix
- AURORA-2 Clinical Site, Tucson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- HonorHealth, Phoenix
- Medical Advancement Centers of Arizona, Phoenix
- Pima Heart and Vascular Clinical Research, Tucson
- i još 1
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Arizona Clinical Trials, Tucson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Helios Clinical Research - Phoenix, Phoenix
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Arizona Clinical Trials, Tucson
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Chandler
- ACCOMPLISH-2 Research Site, Phoenix
- ACCOMPLISH-2 Research Site, Sun City West
- i još 1
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 79 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07654374AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Dignity Health, Mercy Gilbert, Gilbert
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT07571109A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
- Headlands Research - Scottsdale, Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT06143956A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert
- Synexus Clinical Research US, Inc., Phoenix
- Pima Heart, Tucson
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Medical Dermatology Specialists, Phoenix
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Phoenix
- Kailera Clinical Site, Sun City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284901Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Sun City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Gilbert Center for Family Medicine, Gilbert
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Glendale
- Kailera Clinical Site, Phoenix
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. ruj 2026. · NCT07284979The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
- NIDDK, Phoenix, Phoenix
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 60 godina · Oba spola · Ažurirano 28. kol 2026. · NCT05545306Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arizona Clinical Trials, Chandler
- Epic Medical Research - Sun City, Sun City
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 27. kol 2026. · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Mesa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07784725Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
- Exponent Phoenix, Phoenix
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT07776678A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Mercy Gilbert Medical Center, Gilbert
- Sun City Clinical Research, Glendale
- Honor Health, Phoenix
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Phoenix
- ACCOMPLISH-1 Research Site, Sun City West
- ACCOMPLISH-1 Research Site, Tucson
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361Fibrosis Lessens After Metabolic Surgery
- Banner Health Center, Phoenix
U tijeku regrutacijaFaza 4Zdravi dobrovoljci dobrodošli
Od 18 do 75 godina · Oba spola · Ažurirano 31. srp 2026. · NCT06374875A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Arizona Research Center, Inc., Phoenix
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. srp 2026. · NCT07481630A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
- Arizona Liver Health, Chandler
- Adobe Clinical Research, Tucson
U tijeku regrutacijaFaza 1/2
Od 18 do 65 godina · Oba spola · Ažurirano 8. srp 2026. · NCT06836609Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
- Mayo Clinic in Arizona, Scottsdale
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 30 do 70 godina · Oba spola · Ažurirano 28. sij 2026. · NCT04232566Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- The University of Arizona College of Medicine- Phoenix, Phoenix
U tijeku regrutacijaFaza 3
Od 18 do 75 godina · Oba spola · Ažurirano 14. stu 2025. · NCT06499857A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- PRANDIAL Lab, Flagstaff
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 14. stu 2024. · NCT04755062Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.